Compare iShares Global Tech ETF (IXN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares Global Tech ETF trades at $141 (market cap $9.75B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: iShares Global Tech ETF is the larger of the two by market cap, and iShares Global Tech ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Tech ETF for 48 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| IXN | TVTX | |
|---|---|---|
Market Cap | $9.75B | $4.88B |
Volume | 365,991 | 1,668,577 |
Sector | Sector/Thematic | Health |
52-Week High | $152.94 | $67.52 |
52-Week Low | $95.76 | $26.79 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN (iShares Global Tech ETF) trades at $147.07, down 0.49% on the day but maintains a bullish technical signal with strong moving average support. The ETF recently hit a 52-week high, reflecting momentum despite current consolidation. Technical indicators show mixed signals with neutral RSI readings but bearish ADX trends, while support levels cluster around $146-147.
The outlook remains constructive given the ETF's exposure to global technology leaders and attractive valuation metrics. Key risks include concentration in tech stocks and AI sector volatility. Analyst sentiment appears positive with recent buy ratings citing compelling valuations and long-term growth potential in the global tech landscape.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
